J. Wals

1.4k total citations
15 papers, 664 citations indexed

About

J. Wals is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Wals has authored 15 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Wals's work include Cancer Treatment and Pharmacology (6 papers), Neutropenia and Cancer Infections (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). J. Wals is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Neutropenia and Cancer Infections (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). J. Wals collaborates with scholars based in Netherlands. J. Wals's co-authors include Frans Erdkamp, C. J. Rodenburg, Cornelis J.A. Punt, Miriam Koopman, Robert S. de Jong, Ninja Antonini, Gerard Vreugdenhil, Aart van Bochove, P. H. Th. J. Slee and O. J. L. Loosveld and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

J. Wals

15 papers receiving 646 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Wals Netherlands 8 537 190 176 153 102 15 664
Clemens Gießen-Jung Germany 11 499 0.9× 211 1.1× 193 1.1× 115 0.8× 118 1.2× 34 687
Roberto Moretto Italy 15 623 1.2× 263 1.4× 207 1.2× 135 0.9× 178 1.7× 69 872
K C Lakshmaiah India 11 315 0.6× 92 0.5× 186 1.1× 85 0.6× 73 0.7× 28 544
Nicola Borsellino Italy 10 707 1.3× 94 0.5× 330 1.9× 226 1.5× 188 1.8× 19 880
Scot Dowden Canada 14 624 1.2× 122 0.6× 285 1.6× 124 0.8× 188 1.8× 24 826
Kian Fong Foo Singapore 13 320 0.6× 78 0.4× 238 1.4× 129 0.8× 193 1.9× 24 712
Swee‐Peng Yap Singapore 7 287 0.5× 98 0.5× 255 1.4× 45 0.3× 59 0.6× 9 532
Alfonso Yubero Spain 13 486 0.9× 63 0.3× 125 0.7× 54 0.4× 53 0.5× 45 584
D. Braumann Germany 14 331 0.6× 65 0.3× 165 0.9× 174 1.1× 135 1.3× 28 568
A. Misino Italy 11 755 1.4× 106 0.6× 368 2.1× 221 1.4× 133 1.3× 25 983

Countries citing papers authored by J. Wals

Since Specialization
Citations

This map shows the geographic impact of J. Wals's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Wals with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Wals more than expected).

Fields of papers citing papers by J. Wals

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Wals. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Wals. The network helps show where J. Wals may publish in the future.

Co-authorship network of co-authors of J. Wals

This figure shows the co-authorship network connecting the top 25 collaborators of J. Wals. A scholar is included among the top collaborators of J. Wals based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Wals. J. Wals is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Vriens, Birgit E. P. J., Maureen J.B. Aarts, Bart de Vries, et al.. (2013). Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. European Journal of Cancer. 49(15). 3102–3110. 31 indexed citations
2.
Buijsen, Jeroen, Guido Lammering, Rob L. H. Jansen, et al.. (2013). Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiotherapy and Oncology. 107(2). 184–188. 39 indexed citations
3.
Berkmortel, F. Van den, et al.. (2012). Reliability of receptor assessment on core needle biopsy in breast cancer patients. Tumor Biology. 34(2). 987–994. 18 indexed citations
4.
Lalisang, Roy, Frans Erdkamp, C. J. Rodenburg, et al.. (2011). Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy. Breast Cancer Research and Treatment. 128(2). 437–445. 5 indexed citations
5.
Coombes, R. Charles, Judith M. Bliss, Marc Espié, et al.. (2010). DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients.. Journal of Clinical Oncology. 28(15_suppl). 536–536. 1 indexed citations
6.
Koopman, Miriam, Ninja Antonini, J. Wals, et al.. (2007). Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. The Lancet. 370(9582). 135–142. 461 indexed citations
7.
Punt, Cornelis J.A., Miriam Koopman, J. Douma, et al.. (2007). Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study. Journal of Clinical Oncology. 25(18_suppl). 4012–4012. 7 indexed citations
8.
Koopman, Miriam, Ninja Antonini, J. Douma, et al.. (2007). 3015 ORAL Sequential vs. combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC). A Dutch Colorectal Cancer Group (DCCG) phase III study. European Journal of Cancer Supplements. 5(4). 239–240. 1 indexed citations
9.
10.
Erdkamp, F., et al.. (2003). 168 A phase II study of docetaxel, epirubicin, and cispiatin with G-CSF (ienograstim) support in patients with advanced ovarian cancer. European Journal of Cancer Supplements. 1(5). S54–S54. 1 indexed citations
11.
Peters, Frank, et al.. (2001). Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Annals of Hematology. 80(3). 155–159. 37 indexed citations
12.
Peters, Florian, M. Fickers, Frans Erdkamp, et al.. (2001). The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Annals of Hematology. 80(7). 406–410. 20 indexed citations
13.
Hillen, H.F.P., Harry C. Schouten, Roy Lalisang, et al.. (2000). True. British Journal of Cancer. 82(12). 1914–1919. 5 indexed citations
14.
15.
Wils, J., et al.. (1996). PP-7-6 Dose dense epirubicin (E) and paclitaxel (P) with G-CSF in metastatic breast cancer (MBC). European Journal of Cancer. 32. 46–46. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Clemens Gießen-Jung Breakdown of academic impact, for papers by Roberto Moretto Breakdown of academic impact, for papers by K C Lakshmaiah Breakdown of academic impact, for papers by Nicola Borsellino Breakdown of academic impact, for papers by Scot Dowden Breakdown of academic impact, for papers by Kian Fong Foo Breakdown of academic impact, for papers by Swee‐Peng Yap Breakdown of academic impact, for papers by Alfonso Yubero Breakdown of academic impact, for papers by D. Braumann Breakdown of academic impact, for papers by A. Misino
Rankless by CCL
2026